人胰岛素药物市场 - 增长、趋势、COVID-19 影响和预测 (2023 - 2028)

Table of Contents

1. 1. INTRODUCTION

   1. 1.1 Study Assumptions

   2. 1.2 Scope of the Study

2. 2. RESEARCH METHODOLOGY

3. 3. EXECUTIVE SUMMARY

4. 4. MARKET DYNAMICS

   1. 4.1 Market Overview

   2. 4.2 Drivers

   3. 4.3 Restraints

   4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

5. 5. MARKET SEGMENTATION

   1. 5.1 By Product Type

      1. 5.1.1 Basal or Long-acting Insulins (Value and Volume, 2012-2025)

         1. 5.1.1.1 Lantus (Insulin glargine)

         2. 5.1.1.2 Levemir (Insulin detemir)

         3. 5.1.1.3 Toujeo (Insulin glargine)

         4. 5.1.1.4 Tresiba (Insulin degludec)

         5. 5.1.1.5 Basaglar (Insulin glargine)

      2. 5.1.2 Bolus or Fast-acting Insulins (Value and Volume, 2012-2025)

         1. 5.1.2.1 NovoRapid/Novolog (Insulin aspart)

         2. 5.1.2.2 Humalog (Insulin lispro)

         3. 5.1.2.3 Apidra (Insulin glulisine)

         4. 5.1.2.4 FIASP (Insulin aspart)

         5. 5.1.2.5 Admelog (Insulin lispro)

      3. 5.1.3 Traditional Human Insulins (Value and Volume, 2012-2025)

         1. 5.1.3.1 Novolin/Actrapid/Insulatard

         2. 5.1.3.2 Humulin

         3. 5.1.3.3 Insuman

      4. 5.1.4 Combination Insulins (Value and Volume, 2012-2025)

         1. 5.1.4.1 NovoMix (Biphasic Insulin aspart)

         2. 5.1.4.2 Ryzodeg (Insulin degludec/Insulin aspart)

         3. 5.1.4.3 Xultophy (Insulin degludec/Liraglutide)

         4. 5.1.4.4 Soliqua/Suliqua (Insulin glargine/Lixisenatide)

      5. 5.1.5 Biosimilar Insulins (Value and Volume, 2012-2025)

         1. 5.1.5.1 Insulin Glargine Biosimilars

         2. 5.1.5.2 Human Insulin Biosimilars

   2. 5.2 Geography

      1. 5.2.1 North America

         1. 5.2.1.1 United States (Value and Volume, 2012-2025)

            1. 5.2.1.1.1 Basal or Long-acting Insulins

            2. 5.2.1.1.2 Bolus or Fast-acting Insulins

            3. 5.2.1.1.3 Traditional Human Insulins

            4. 5.2.1.1.4 Combination Insulins

            5. 5.2.1.1.5 Biosimilar Insulins

         2. 5.2.1.2 Canada (Value and Volume, 2012-2025)

            1. 5.2.1.2.1 Basal or Long-acting Insulins

            2. 5.2.1.2.2 Bolus or Fast-acting Insulins

            3. 5.2.1.2.3 Traditional Human Insulins

            4. 5.2.1.2.4 Combination Insulins

            5. 5.2.1.2.5 Biosimilar Insulins

         3. 5.2.1.3 Rest of North America (Value and Volume, 2012-2025)

            1. 5.2.1.3.1 Basal or Long-acting Insulins

            2. 5.2.1.3.2 Bolus or Fast-acting Insulins

            3. 5.2.1.3.3 Traditional Human Insulins

            4. 5.2.1.3.4 Combination Insulins

            5. 5.2.1.3.5 Biosimilar Insulins

      2. 5.2.2 Europe

         1. 5.2.2.1 France (Value and Volume, 2012-2025)

            1. 5.2.2.1.1 Basal or Long-acting Insulins

            2. 5.2.2.1.2 Bolus or Fast-acting Insulins

            3. 5.2.2.1.3 Traditional Human Insulins

            4. 5.2.2.1.4 Combination Insulins

            5. 5.2.2.1.5 Biosimilar Insulins

         2. 5.2.2.2 Germany (Value and Volume, 2012-2025)

            1. 5.2.2.2.1 Basal or Long-acting Insulins

            2. 5.2.2.2.2 Bolus or Fast-acting Insulins

            3. 5.2.2.2.3 Traditional Human Insulins

            4. 5.2.2.2.4 Combination Insulins

            5. 5.2.2.2.5 Biosimilar Insulins

         3. 5.2.2.3 Italy (Value and Volume, 2012-2025)

            1. 5.2.2.3.1 Basal or Long-acting Insulins

            2. 5.2.2.3.2 Bolus or Fast-acting Insulins

            3. 5.2.2.3.3 Traditional Human Insulins

            4. 5.2.2.3.4 Combination Insulins

            5. 5.2.2.3.5 Biosimilar Insulins

         4. 5.2.2.4 Spain (Value and Volume, 2012-2025)

            1. 5.2.2.4.1 Basal or Long-acting Insulins

            2. 5.2.2.4.2 Bolus or Fast-acting Insulins

            3. 5.2.2.4.3 Traditional Human Insulins

            4. 5.2.2.4.4 Combination Insulins

            5. 5.2.2.4.5 Biosimilar Insulins

         5. 5.2.2.5 United Kingdom (Value and Volume, 2012-2025)

            1. 5.2.2.5.1 Basal or Long-acting Insulins

            2. 5.2.2.5.2 Bolus or Fast-acting Insulins

            3. 5.2.2.5.3 Traditional Human Insulins

            4. 5.2.2.5.4 Combination Insulins

            5. 5.2.2.5.5 Biosimilar Insulins

         6. 5.2.2.6 Russia (Value and Volume, 2012-2025)

            1. 5.2.2.6.1 Basal or Long-acting Insulins

            2. 5.2.2.6.2 Bolus or Fast-acting Insulins

            3. 5.2.2.6.3 Traditional Human Insulins

            4. 5.2.2.6.4 Combination Insulins

            5. 5.2.2.6.5 Biosimilar Insulins

         7. 5.2.2.7 Rest of Europe (Value and Volume, 2012-2025)

            1. 5.2.2.7.1 Basal or Long-acting Insulins

            2. 5.2.2.7.2 Bolus or Fast-acting Insulins

            3. 5.2.2.7.3 Traditional Human Insulins

            4. 5.2.2.7.4 Combination Insulins

            5. 5.2.2.7.5 Biosimilar Insulins

      3. 5.2.3 Latin America

         1. 5.2.3.1 Mexico (Value and Volume, 2012-2025)

            1. 5.2.3.1.1 Basal or Long-acting Insulins

            2. 5.2.3.1.2 Bolus or Fast-acting Insulins

            3. 5.2.3.1.3 Traditional Human Insulins

            4. 5.2.3.1.4 Combination Insulins

            5. 5.2.3.1.5 Biosimilar Insulins

         2. 5.2.3.2 Brazil (Value and Volume, 2012-2025)

            1. 5.2.3.2.1 Basal or Long-acting Insulins

            2. 5.2.3.2.2 Bolus or Fast-acting Insulins

            3. 5.2.3.2.3 Traditional Human Insulins

            4. 5.2.3.2.4 Combination Insulins

            5. 5.2.3.2.5 Biosimilar Insulins

         3. 5.2.3.3 Rest of Latin America (Value and Volume, 2012-2025)

            1. 5.2.3.3.1 Basal or Long-acting Insulins

            2. 5.2.3.3.2 Bolus or Fast-acting Insulins

            3. 5.2.3.3.3 Traditional Human Insulins

            4. 5.2.3.3.4 Combination Insulins

            5. 5.2.3.3.5 Biosimilar Insulins

      4. 5.2.4 Asia-Pacific

         1. 5.2.4.1 Japan (Value and Volume, 2012-2025)

            1. 5.2.4.1.1 Basal or Long-acting Insulins

            2. 5.2.4.1.2 Bolus or Fast-acting Insulins

            3. 5.2.4.1.3 Traditional Human Insulins

            4. 5.2.4.1.4 Combination Insulins

            5. 5.2.4.1.5 Biosimilar Insulins

         2. 5.2.4.2 South Korea (Value and Volume, 2012-2025)

            1. 5.2.4.2.1 Basal or Long-acting Insulins

            2. 5.2.4.2.2 Bolus or Fast-acting Insulins

            3. 5.2.4.2.3 Traditional Human Insulins

            4. 5.2.4.2.4 Combination Insulins

            5. 5.2.4.2.5 Biosimilar Insulins

         3. 5.2.4.3 China (Value and Volume, 2012-2025)

            1. 5.2.4.3.1 Basal or Long-acting Insulins

            2. 5.2.4.3.2 Bolus or Fast-acting Insulins

            3. 5.2.4.3.3 Traditional Human Insulins

            4. 5.2.4.3.4 Combination Insulins

            5. 5.2.4.3.5 Biosimilar Insulins

         4. 5.2.4.4 India (Value and Volume, 2012-2025)

            1. 5.2.4.4.1 Basal or Long-acting Insulins

            2. 5.2.4.4.2 Bolus or Fast-acting Insulins

            3. 5.2.4.4.3 Traditional Human Insulins

            4. 5.2.4.4.4 Combination Insulins

            5. 5.2.4.4.5 Biosimilar Insulins

         5. 5.2.4.5 Australia (Value and Volume, 2012-2025)

            1. 5.2.4.5.1 Basal or Long-acting Insulins

            2. 5.2.4.5.2 Bolus or Fast-acting Insulins

            3. 5.2.4.5.3 Traditional Human Insulins

            4. 5.2.4.5.4 Combination Insulins

            5. 5.2.4.5.5 Biosimilar Insulins

         6. 5.2.4.6 Vietnam (Value and Volume, 2012-2025)

            1. 5.2.4.6.1 Basal or Long-acting Insulins

            2. 5.2.4.6.2 Bolus or Fast-acting Insulins

            3. 5.2.4.6.3 Traditional Human Insulins

            4. 5.2.4.6.4 Combination Insulins

            5. 5.2.4.6.5 Biosimilar Insulins

         7. 5.2.4.7 Malaysia (Value and Volume, 2012-2025)

            1. 5.2.4.7.1 Basal or Long-acting Insulins

            2. 5.2.4.7.2 Bolus or Fast-acting Insulins

            3. 5.2.4.7.3 Traditional Human Insulins

            4. 5.2.4.7.4 Combination Insulins

            5. 5.2.4.7.5 Biosimilar Insulins

         8. 5.2.4.8 Indonesia (Value and Volume, 2012-2025)

            1. 5.2.4.8.1 Basal or Long-acting Insulins

            2. 5.2.4.8.2 Bolus or Fast-acting Insulins

            3. 5.2.4.8.3 Traditional Human Insulins

            4. 5.2.4.8.4 Combination Insulins

            5. 5.2.4.8.5 Biosimilar Insulins

         9. 5.2.4.9 Philippines (Value and Volume, 2012-2025)

            1. 5.2.4.9.1 Basal or Long-acting Insulins

            2. 5.2.4.9.2 Bolus or Fast-acting Insulins

            3. 5.2.4.9.3 Traditional Human Insulins

            4. 5.2.4.9.4 Combination Insulins

            5. 5.2.4.9.5 Biosimilar Insulins

         10. 5.2.4.10 Thailand (Value and Volume, 2012-2025)

             1. 5.2.4.10.1 Basal or Long-acting Insulins

             2. 5.2.4.10.2 Bolus or Fast-acting Insulins

             3. 5.2.4.10.3 Traditional Human Insulins

             4. 5.2.4.10.4 Combination Insulins

             5. 5.2.4.10.5 Biosimilar Insulins

         11. 5.2.4.11 Rest of Asia-Pacific (Value and Volume, 2012-2025)

             1. 5.2.4.11.1 Basal or Long-acting Insulins

             2. 5.2.4.11.2 Bolus or Fast-acting Insulins

             3. 5.2.4.11.3 Traditional Human Insulins

             4. 5.2.4.11.4 Combination Insulins

             5. 5.2.4.11.5 Biosimilar Insulins

      5. 5.2.5 Middle-East and Africa

         1. 5.2.5.1 Saudi Arabia (Value and Volume, 2012-2025)

            1. 5.2.5.1.1 Basal or Long-acting Insulins

            2. 5.2.5.1.2 Bolus or Fast-acting Insulins

            3. 5.2.5.1.3 Traditional Human Insulins

            4. 5.2.5.1.4 Combination Insulins

            5. 5.2.5.1.5 Biosimilar Insulins

         2. 5.2.5.2 Iran (Value and Volume, 2012-2025)

            1. 5.2.5.2.1 Basal or Long-acting Insulins

            2. 5.2.5.2.2 Bolus or Fast-acting Insulins

            3. 5.2.5.2.3 Traditional Human Insulins

            4. 5.2.5.2.4 Combination Insulins

            5. 5.2.5.2.5 Biosimilar Insulins

         3. 5.2.5.3 Egypt (Value and Volume, 2012-2025)

            1. 5.2.5.3.1 Basal or Long-acting Insulins

            2. 5.2.5.3.2 Bolus or Fast-acting Insulins

            3. 5.2.5.3.3 Traditional Human Insulins

            4. 5.2.5.3.4 Combination Insulins

            5. 5.2.5.3.5 Biosimilar Insulins

         4. 5.2.5.4 Oman (Value and Volume, 2012-2025)

            1. 5.2.5.4.1 Basal or Long-acting Insulins

            2. 5.2.5.4.2 Bolus or Fast-acting Insulins

            3. 5.2.5.4.3 Traditional Human Insulins

            4. 5.2.5.4.4 Combination Insulins

            5. 5.2.5.4.5 Biosimilar Insulins

         5. 5.2.5.5 South Africa (Value and Volume, 2012-2025)

            1. 5.2.5.5.1 Basal or Long-acting Insulins

            2. 5.2.5.5.2 Bolus or Fast-acting Insulins

            3. 5.2.5.5.3 Traditional Human Insulins

            4. 5.2.5.5.4 Combination Insulins

            5. 5.2.5.5.5 Biosimilar Insulins

         6. 5.2.5.6 Rest of Middle-East and Africa (Value and Volume, 2012-2025)

            1. 5.2.5.6.1 Basal or Long-acting Insulins

            2. 5.2.5.6.2 Bolus or Fast-acting Insulins

            3. 5.2.5.6.3 Traditional Human Insulins

            4. 5.2.5.6.4 Combination Insulins

            5. 5.2.5.6.5 Biosimilar Insulins

6. 6. MARKET INDICATORS

   1. 6.1 Type 1 Diabetes Population (2012-2025)

   2. 6.2 Type 2 Diabetes Population (2012-2025)

7. 7. COMPETITIVE LANDSCAPE

   1. 7.1 COMPANY PROFILES

      1. 7.1.1 Novo Nordisk A/S

         1. 7.1.1.1 Overview

         2. 7.1.1.2 Products and Strategies

         3. 7.1.1.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

         4. 7.1.1.4 Ratio Analysis (5 Years)

         5. 7.1.1.5 Strength and Stability Analysis (5 Years)

         6. 7.1.1.6 Recent Developments

      2. 7.1.2 Sanofi S.A.

         1. 7.1.2.1 Overview

         2. 7.1.2.2 Products and Strategies

         3. 7.1.2.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

         4. 7.1.2.4 Ratio Analysis (5 Years)

         5. 7.1.2.5 Strength and Stability Analysis (5 Years)

         6. 7.1.2.6 Recent Developments

      3. 7.1.3 Eli Lilly and Company

         1. 7.1.3.1 Overview

         2. 7.1.3.2 Products and Strategies

         3. 7.1.3.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

         4. 7.1.3.4 Ratio Analysis (5 Years)

         5. 7.1.3.5 Strength and Stability Analysis (5 Years)

         6. 7.1.3.6 Recent Developments

      4. 7.1.4 Biocon Limited

         1. 7.1.4.1 Overview

         2. 7.1.4.2 Products and Strategies

         3. 7.1.4.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

         4. 7.1.4.4 Ratio Analysis (5 Years)

         5. 7.1.4.5 Strength and Stability Analysis (5 Years)

         6. 7.1.4.6 Recent Developments

      5. 7.1.5 Pfizer Inc.

         1. 7.1.5.1 Overview

         2. 7.1.5.2 Products and Strategies

         3. 7.1.5.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

         4. 7.1.5.4 Ratio Analysis (5 Years)

         5. 7.1.5.5 Strength and Stability Analysis (5 Years)

         6. 7.1.5.6 Recent Developments

      6. 7.1.6 Wockhardt

         1. 7.1.6.1 Overview

         2. 7.1.6.2 Products and Strategies

         3. 7.1.6.3 Financial Benchmarking (Ratio Comparisons with Industry Standards)

         4. 7.1.6.4 Ratio Analysis (5 Years)

         5. 7.1.6.5 Strength and Stability Analysis (5 Years)

         6. 7.1.6.6 Recent Developments

      7. 7.1.7 Julphar

         1. 7.1.7.1 Overview

         2. 7.1.7.2 Products and Strategies

         3. 7.1.7.3 Recent Developments

      8. 7.1.8 Exir

         1. 7.1.8.1 Overview

         2. 7.1.8.2 Products and Strategies

         3. 7.1.8.3 Recent Developments

      9. 7.1.9 Sedico

         1. 7.1.9.1 Overview

         2. 7.1.9.2 Products and Strategies

         3. 7.1.9.3 Recent Developments

   3. 7.2 COMPANY SHARE ANALYSIS

      1. 7.2.1 Novo Nordisk AS

      2. 7.2.2 Sanofi Aventis

      3. 7.2.3 Eli Lilly

      4. 7.2.4 Other Companies

8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS